Chugai gets rights to prostate cancer test:
This article was originally published in Clinica
Executive Summary
Japanese company Chugai has obtained the worldwide rights to a system for diagnosing prostate cancer from Finnish company EG&G Wallac. Chugai has set up a wholly-owned diagnostic subsidiary, Chugai Diagnostics Science, which is expected to be operational in October. The system assesses free PSA and complex PSA levels in the bloodstream with a manually-operated measuring device, reports Reuters.